Physician

Julianne W Childs, D.O.

According to 2025 Medicare claims, Julianne Childs, D.O. (NPI: 1639166101) practices hematology/oncology in the Atlantic City-Hammonton, NJ market, with the plurality of this provider's patient population coming from Cape May, NJ. This provider's primary affiliated billing organization is REGIONAL CANCER CARE ASSOCIATES LLC (NPI: 1801850243; TIN: 223141761) and primary practice location at 08223-1271.

Childs' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 698 traditional Medicare patients, billed 245,457 HCPCS/CPT codes, and received $2,387,200 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,449 prescription claims across 245 beneficiaries totaling $3,093,076 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 12 claims. Open Payments data shows 97 records totaling $1,997. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $395,233 to $3,093,076. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	855	156,297	$1,573,717
2016	923	148,620	$1,642,791
2017	948	160,513	$1,759,733
2018	827	152,178	$1,840,991
2019	763	183,392	$2,173,030
2020	672	177,515	$1,888,952
2021	660	208,208	$2,285,044
2022	668	190,400	$2,160,485
2023	702	216,610	$2,446,114
2024	698	245,457	$2,387,200

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	215	1,113	$395,233
2016	192	941	$600,320
2017	235	1,124	$1,287,364
2018	242	1,127	$1,871,236
2019	244	1,235	$2,092,627
2020	218	1,027	$1,879,912
2021	212	1,037	$1,715,459
2022	235	1,163	$1,869,737
2023	229	1,189	$1,946,230
2024	245	1,449	$3,093,076

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	11	106	$6,372
2016	N/R	192	$45,584
2017	N/R	104	$16,174
2018	N/R	N/R	N/R
2019	N/R	74	$9,030
2020	N/R	29	$2,904
2021	N/R	N/R	N/R
2022	N/R	22	$1,293
2023	N/R	11	$113
2024	N/R	12	$401

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	412	943	$101
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	168	286	$72
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	246	511	$13
36415	Insertion of needle into vein for collection of blood sample	541	2,065	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	561	2,175	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	47	1,470	$863,102
Pomalyst	Pomalidomide	32	896	$727,314
Revlimid	Lenalidomide	19	532	$335,915
Ibrance	Palbociclib	21	588	$326,924
Promacta	Eltrombopag Olamine	24	720	$240,273

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	12	$401

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	97	$1,997	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Julianne W. Childs, D.O.?

Tedicare shows public-source Medicare data for Julianne W. Childs, D.O. (NPI 1639166101), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Julianne W. Childs, D.O. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Julianne W. Childs, D.O.?

Julianne W. Childs, D.O. is linked to REGIONAL CANCER CARE ASSOCIATES LLC (billing NPI 1801850243) in the available physician profile data.

Does Julianne W. Childs, D.O. have Open Payments data?

Julianne W. Childs, D.O. has 97 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.